Glucagon-like Peptide 1 Global Market Report 2025

Description

Glucagon-like peptide 1 (GLP-1) is a peptide hormone derived from amino acids and produced in the L-cells of the intestinal epithelial endocrine. This hormone is employed in the treatment of diseases such as diabetes and obesity.

The primary product types of glucagon-such as peptide 1 include Trulicity, Ozempic, Victoza, Rybelsus, and others. Trulicity, a prescription medicine administered through injection, is designed to enhance blood sugar levels. Various routes of administration, including oral, parenteral, and others, are utilized in settings such as hospitals, specialty clinics, and more.

The glucagon-such as peptide 1 market research report is one of a series of new reports from The Business Research Company that provides glucagon-such as peptide 1 market statistics, including glucagon-such as peptide 1 industry global market size, regional shares, competitors with a glucagon-such as peptide 1 market share, detailed glucagon-such as peptide 1 market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-such as peptide 1 industry. This glucagon-such as peptide 1 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from$20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to rising prevalence of diabetes, focus on improved diabetes management, patient preference for injectable therapies, clinical efficacy and safety profiles, advancements in diabetes research

The glucagon-like peptide 1 market size is expected to see strong growth in the next few years. It will grow to $31.27 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to emergence of oral glp-1 therapies, focus on personalized medicine, integration in diabetes treatment algorithms, patient-centric approaches in healthcare. Major trends in the forecast period include market expansion in emerging economies, regulatory approvals for new formulations, focus on personalized medicine, patient education and awareness programs, competitive landscape dynamics.

The global glucagon-such as peptide 1 market is anticipated to experience growth due to the rising prevalence of diabetes. Diabetes, characterized by elevated blood sugar levels, is a condition that glucagon-such as peptide 1 medications address, particularly in the context of type 2 diabetes, offering potential benefits such as weight loss and improved blood sugar control. As of January 2022, global diabetes prevalence in individuals aged 20-79 was estimated at 10.5% (536.6 million people), with a projected increase to 12.2% (783.2 million) by 2045, according to the National Library of Medicine. Consequently, the escalating prevalence of diabetes is expected to be a driving force for the glucagon-such as peptide 1 market.

The growth of the glucagon-such as peptide 1 (GLP-1) market is further expected to be fueled by an increasing emphasis on personalized medicine. Personalized medicine involves tailoring prevention, detection, or treatment approaches based on an individual's genetic or protein-related information. This approach enables the customization of GLP-1 formulations and dosages according to the specific needs and preferences of each patient. In 2022, the US Food and Drug Administration (FDA) approved 12 personalized medicines, constituting approximately 34% of all newly approved therapeutic molecular entities, as reported by the Personalized Medicine Coalition. Thus, the growing emphasis on personalized medicine serves as a catalyst for the glucagon-such as peptide 1 (GLP-1) market's expansion.

Technological innovations are emerging as a prominent trend in the global glucagon-such as peptide 1 market. Major companies within the market are introducing novel technologies to maintain their competitive positions. For example, Novo Nordisk A/S, a pharmaceutical company based in Denmark, has launched Wegovy, a groundbreaking once-weekly glucagon-such as peptide 1 therapy designed for weight management. Successfully completing the STEP Phase 3a clinical trial program, Wegovy demonstrated a safe and well-tolerated profile, making it an effective option for individuals struggling with obesity to achieve and sustain weight loss.

Leading companies in the glucagon-such as peptide 1 market are strategically focusing on product innovations, such as the development of oral semaglutide, to ensure their continued market presence. Oral semaglutide is a diabetes management medication delivered in pill form and taken orally. Novo Nordisk India, a healthcare company based in India, introduced oral semaglutide in January 2022. This peptide-in-a-pill formulation represents a groundbreaking advancement in diabetes treatment, providing patients with an oral alternative to injections. The innovation addresses challenges related to peptide degradation in the stomach, enhancing both stability and absorption.

In March 2024, Novo Holdings A/S, an investment company based in Denmark, acquired Catalent Inc. for $16.5 billion. This acquisition is intended to enhance Novo Holdings' presence in the rapidly growing GLP-1 market by utilizing Catalent's established infrastructure in fill-finish manufacturing. This move aims to increase capacity to meet the rising demand for treatments related to diabetes and weight loss. Catalent Inc. is a biotechnology company located in the United States that specializes in advanced delivery technologies and development solutions for pharmaceuticals.

Major companies operating in the glucagon-like peptide 1 market include Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc, Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd, Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc, ConjuChem Biotechnologies, MannKind Corporation:, Provention Bio Inc, Regeneron Pharmaceuticals

North America was the largest region in the glucagon-such as peptide 1 market in 2024. The regions covered in the glucagon-such as peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the glucagon-such as peptide 1 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The glucagon-such as peptide 1 market consists of sales of dulaglutide, albiglutide, semaglutide, and tirzepatide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Glucagon-like Peptide 1 Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glucagon-like peptide 1 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glucagon-like peptide 1 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glucagon-like peptide 1 market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product: Trulicity; Ozempic; Victoza; Rybelsus; Other Types
2) By Route of Administration: Oral; Parenteral; Other Routes
3) By End-Users: Hospitals; Specialty Clinics; Other End Users
Subsegments:
1) By Trulicity: Injection (pre-filled pen); Dosage forms (0.75 mg, 1.5 mg, etc.)
2) By Ozempic: Injection (pre-filled pen); Dosage forms (0.5 mg, 1 mg, etc.)
3) By Victoza: Injection (pre-filled pen); Dosage forms (1.2 mg, 1.8 mg, etc.)
4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)
5) By Other Types: Experimental formulations; Combination products with other medications; Alternative delivery systems
Companies Mentioned: Novo Nordisk AS; Sanofi SA; Eli Lilly and Co; AstraZeneca plc; Pfizer Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r24168

1. Executive Summary

2. Glucagon-like Peptide 1 Market Characteristics

3. Glucagon-like Peptide 1 Market Trends And Strategies

4. Glucagon-like Peptide 1 Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Glucagon-like Peptide 1 Growth Analysis And Strategic Analysis Framework

5.1. Global Glucagon-like Peptide 1 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Glucagon-like Peptide 1 Market Growth Rate Analysis
5.4. Global Glucagon-like Peptide 1 Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Glucagon-like Peptide 1 Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Glucagon-like Peptide 1 Total Addressable Market (TAM)

6. Glucagon-like Peptide 1 Market Segmentation

6.1. Global Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Trulicity
Ozempic
Victoza
Rybelsus
Other Types
6.2. Global Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Routes
6.3. Global Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Other End Users
6.4. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Trulicity, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injection (pre-filled pen)
Dosage forms (0.75 mg, 1.5 mg, etc.)
6.5. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Ozempic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injection (pre-filled pen)
Dosage forms (0.5 mg, 1 mg, etc.)
6.6. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Victoza, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injection (pre-filled pen)
Dosage forms (1.2 mg, 1.8 mg, etc.)
6.7. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Rybelsus, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral tablet (3 mg, 7 mg, 14 mg)
6.8. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Experimental formulations
Combination products with other medications
Alternative delivery systems

7. Glucagon-like Peptide 1 Market Regional And Country Analysis

7.1. Global Glucagon-like Peptide 1 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Glucagon-like Peptide 1 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Glucagon-like Peptide 1 Market

8.1. Asia-Pacific Glucagon-like Peptide 1 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Glucagon-like Peptide 1 Market

9.1. China Glucagon-like Peptide 1 Market Overview
9.2. China Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Glucagon-like Peptide 1 Market

10.1. India Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Glucagon-like Peptide 1 Market

11.1. Japan Glucagon-like Peptide 1 Market Overview
11.2. Japan Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Glucagon-like Peptide 1 Market

12.1. Australia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Glucagon-like Peptide 1 Market

13.1. Indonesia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Glucagon-like Peptide 1 Market

14.1. South Korea Glucagon-like Peptide 1 Market Overview
14.2. South Korea Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Glucagon-like Peptide 1 Market

15.1. Western Europe Glucagon-like Peptide 1 Market Overview
15.2. Western Europe Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Glucagon-like Peptide 1 Market

16.1. UK Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Glucagon-like Peptide 1 Market

17.1. Germany Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Glucagon-like Peptide 1 Market

18.1. France Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Glucagon-like Peptide 1 Market

19.1. Italy Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Glucagon-like Peptide 1 Market

20.1. Spain Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Glucagon-like Peptide 1 Market

21.1. Eastern Europe Glucagon-like Peptide 1 Market Overview
21.2. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Glucagon-like Peptide 1 Market

22.1. Russia Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Glucagon-like Peptide 1 Market

23.1. North America Glucagon-like Peptide 1 Market Overview
23.2. North America Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Glucagon-like Peptide 1 Market

24.1. USA Glucagon-like Peptide 1 Market Overview
24.2. USA Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Glucagon-like Peptide 1 Market

25.1. Canada Glucagon-like Peptide 1 Market Overview
25.2. Canada Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Glucagon-like Peptide 1 Market

26.1. South America Glucagon-like Peptide 1 Market Overview
26.2. South America Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Glucagon-like Peptide 1 Market

27.1. Brazil Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Glucagon-like Peptide 1 Market

28.1. Middle East Glucagon-like Peptide 1 Market Overview
28.2. Middle East Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Glucagon-like Peptide 1 Market

29.1. Africa Glucagon-like Peptide 1 Market Overview
29.2. Africa Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Glucagon-like Peptide 1 Market Competitive Landscape And Company Profiles

30.1. Glucagon-like Peptide 1 Market Competitive Landscape
30.2. Glucagon-like Peptide 1 Market Company Profiles
- 30.2.1. Novo Nordisk AS Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Eli Lilly and Co Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis

31. Glucagon-like Peptide 1 Market Other Major And Innovative Companies

31.1. Boehringer Ingelheim International GmbH
31.2. F Hoffmann-La Roche Ltd
31.3. Bristol-Myers Squibb Company
31.4. Baxter
31.5. Hikma Pharmaceuticals plc
31.6. Zealand Pharma A/S
31.7. Intarcia Therapeutics Inc.
31.8. GlaxoSmithKline plc
31.9. Jiangsu Hansoh Pharmaceutical Group Co Ltd
31.10. Shanghai Benemae Pharmaceutical Corporation
31.11. Adocia
31.12. Biocon
31.13. Hanmi Pharmaceutical Co Ltd
31.14. Ligand Pharmaceuticals Incorporated
31.15. Advinus Therapeutics Ltd

32. Global Glucagon-like Peptide 1 Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Glucagon-like Peptide 1 Market

34. Recent Developments In The Glucagon-like Peptide 1 Market

35. Glucagon-like Peptide 1 Market High Potential Countries, Segments and Strategies

35.1 Glucagon-like Peptide 1 Market In 2029 - Countries Offering Most New Opportunities
35.2 Glucagon-like Peptide 1 Market In 2029 - Segments Offering Most New Opportunities
35.3 Glucagon-like Peptide 1 Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer